Table 2.

HPA survival analysis of 176 PDAC patients (median follow-up 1.27 years) showed that EIF2A, STAM, ANXA2, and AHNAK2 were strong prognostic biomarkers (P < 0.001), i.e., high expression with low 5-year survival and vice versa

Protein	Median expression	P value	High expression with 5-year survival (%)	Low expression with 5-year survival (%)
EIF2A	51.77	0.000083	11	41
STAM	17.2	0.00080	14	43
ANXA2	1995.77	0.000014	11	43
AHNAK2	45.17	0.000066	20	54